N-benzyl-9-tert-butyl-2-chloropurin-6-amine | 1233884-48-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: N-benzyl-9-tert-butyl-2-chloropurin-6-amine
• CAS: 1233884-48-4
• 化学式: C₁₆H₁₈ClN₅
• 分子量: 315.805
• InChiKey: KDDCLDSVVLJRBS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  9-(tert-butyl)-2,6-dichloro-9H-purine 、 苄胺 以 四氢呋喃 为溶剂， 反应 5.0h， 以91%的产率得到N-benzyl-9-tert-butyl-2-chloropurin-6-amine
  参考文献：
  名称：

  N-Alkylation of 2,6-Dichloropurine Hydrochloride with a Variety of Alcohols over Alumina Catalyst

  摘要：

  2,6-Dichloropurine hydrochloride reacts with various types of alcohols using different alumina catalysts and converts into its N-9-alkyl-2-chloro-6-hydroxy-9H-purine products to an extent of 49-74%. The product selectivity depends on the stability of carbocation generated from the alcohol. More stable carbocation formulates both N-7 and N-9-alkyl-2,6-dichloropurine products, whereas the less stable carbocation results in exclusively N-9-alkyl-2-chloro-6-hydroxy-9H-purine. The catalytic activity of alumina prepared using the sol-gel method has larger Brunauer, Emmett, and Teller (BET) surface area and hence shows significantly greater catalytic activity than the commercially available alumina samples.

  DOI：

  10.1080/00397910903162791

文献信息

• ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF
  申请人：Chen Lijing

  公开号：US20180072742A1

  公开（公告）日：2018-03-15

  The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.

  该发明涉及新颖的杂环化合物及其药物制剂。该发明还涉及使用该新颖杂环化合物治疗或预防癌症的方法。
• Ectonucleotidase inhibitors and methods of use thereof
  申请人：Calithera Biosciences, Inc.

  公开号：US10472364B2

  公开（公告）日：2019-11-12

  The invention relates to novel heterocyclic compounds having CD73 inhibitory activity and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.

  本发明涉及具有 CD73 抑制活性的新型杂环化合物及其药物制剂。本发明还涉及使用本发明的新型杂环化合物治疗或预防癌症的方法。
• Ectonucleotidase Inhibitors and Methods of Use Thereof
  申请人：Calithera Biosciences, Inc.

  公开号：US20180186827A1

  公开（公告）日：2018-07-05

  The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
• N-Alkylation of 2,6-Dichloropurine Hydrochloride with a Variety of Alcohols over Alumina Catalyst
  作者：Harikrishna Tumma、N. Nagaraju、K. Vijayakumar Reddy

  DOI：10.1080/00397910903162791

  日期：2010.5.19

  2,6-Dichloropurine hydrochloride reacts with various types of alcohols using different alumina catalysts and converts into its N-9-alkyl-2-chloro-6-hydroxy-9H-purine products to an extent of 49-74%. The product selectivity depends on the stability of carbocation generated from the alcohol. More stable carbocation formulates both N-7 and N-9-alkyl-2,6-dichloropurine products, whereas the less stable carbocation results in exclusively N-9-alkyl-2-chloro-6-hydroxy-9H-purine. The catalytic activity of alumina prepared using the sol-gel method has larger Brunauer, Emmett, and Teller (BET) surface area and hence shows significantly greater catalytic activity than the commercially available alumina samples.